EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis

Nabil K El Ayoubi iD, Fares Fahd, Hani Tamim, Salem Hannoun iD, Mark Bal, Elham El-Hallak, Samia J Khoury iD

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70142 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Nabil K El Ayoubi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nehme and Therese Tohme Multiple Sclerosis Center, Department of Neurology, American University of Beirut, Beirut, Lebanon. Hauptthemen laut MEDLINE: Rituximab, Immunologic Factors, Multiple Sclerosis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We aimed to investigate the comparative effectiveness of standard versus personalized extended interval dosing of anti‐CD20 therapy on clinical and sub‐clinical outcomes in multiple sclerosis.

Methods

Clinical information was collected prospectively on Research Electronic Data Capture. Patients with age ≥ 18 years old, confirmed diagnosis of multiple sclerosis, treatment with B‐cell depleting drug (Rituximab and Ocrelizumab), and minimum follow‐up of 12 months with at least 3 clinical visits and at least 3 infusions of medication were included and divided into an extended interval dosing group, a standard interval dosing group, and a converters group who switched from standard to extended interval dosing. Retinal measures were obtained using spectral domain Optical Coherence Tomography. Magnetic resonance imaging acquisitions were performed in two centers using a standardized conventional imaging protocol for multiple sclerosis.

Results

Patients had a median clinical follow‐up of 3.5 (0.44–7.3) years, retinal OCT follow‐up of 2.6 (1.4) years, and MRI follow‐up of 2.6 (1.1) years. Annualized changes in clinical measures, retinal measures, and brain volumetric measures were similar between the 3 groups. Multivariate regression analyses also showed no differences.

Interpretation

We found no differences in clinical or sub‐clinical outcomes between patients treated with standard interval dosing, patients converting from standard to extended interval dosing, and patients on extended interval dosing of B‐cell depleting drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabImmunologic FactorsMultiple SclerosisAntibodies, Monoclonal, HumanizedHumansFemaleAdultMaleMiddle AgedTomography, Optical CoherenceFollow-Up StudiesMagnetic Resonance Imaging

Stichwörter der Autor:innen

B‐cell depletiondisease outcomesmultiple sclerosis

Substanzen

RituximabocrelizumabImmunologic FactorsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Nehme and Therese Tohme Multiple Sclerosis Center, Department of Neurology, American University of Beirut, Beirut, Lebanon.
  • Department of Neurology, American University of Beirut and Medical Center, Beirut, Lebanon.
  • Department of Internal Medicine, Clinical Research Institute, American University of Beirut Medical Center, Beirut, Lebanon.
  • College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
  • Faculty of Medicine, American University of Beirut, Beirut, Lebanon.

ORCID-Profile: Nabil K El Ayoubi, Salem Hannoun, Samia J Khoury

Zitieren

APA

El Ayoubi, N. K., Fahd, F., Tamim, H., Hannoun, S., Bal, M., El-Hallak, E., & Khoury, S. J. (2025). Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70142

Vancouver

El Ayoubi NK, Fahd F, Tamim H, Hannoun S, Bal M, El-Hallak E, et al. Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70142

BibTeX
@article{ElAyoubi2025,
  author = {El Ayoubi, Nabil K and Fahd, Fares and Tamim, Hani and Hannoun, Salem and Bal, Mark and El-Hallak, Elham and Khoury, Samia J},
  title = {Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70142}
}
Kostenlos starten →